• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Bayer HealthCare - Articles and news items

prostate-cancer-drug-approved-nhs

NICE recommends Bayer’s prostate cancer drug for routine NHS use

Industry news / 2 September 2016 / Niamh Louise Marriott, Digital Content Producer

NICE has today issued draft final guidance recommending radium-223 dichloride (Xofigo, Bayer) as an option for treating prostate cancer…

cost-effective cdf pills and money

NICE says Bayer’s liver cancer drug is not cost-effective

Industry news / 24 August 2016 / The National Institute for Health and Care Excellence (NICE)

NICE originally published guidance in 2010 which said that sorafenib was not cost effective but it was then made available through the CDF. NICE is reconsidering sorafenib as part of its programme to appraise drugs that are currently available…

regorafenib

Regorafenib increases overall survival in hepatocellular carcinoma study

Industry news / 29 June 2016 / Victoria White, Digital Content Producer

Results from the Phase III RESORCE trial investigating Bayer’s regorafenib in patients with unresectable hepatocellular carcinoma have been announced…

eu referendum

Leaving EU could be a setback for Life Sciences in the UK

Blog / 8 June 2016 / Dr Alexander Moscho, Bayer UK & Ireland CEO

In this opinion piece, Dr Alexander Moscho, Bayer UK & Ireland CEO, says a vote to leave the EU will deter investment and make it harder for patients to access new medicines…

BAY-1841788

Bayer and Orion expand BAY-1841788 programme in prostate cancer

Industry news / 3 June 2016 / Victoria White, Digital Content Producer

The Phase III study ARASENS will evaluate BAY-1841788 in men with newly diagnosed metastatic hormone-sensitive prostate cancer…

riociguat

Bayer terminates its Phase II riociguat PH-IIP trial

Industry news / 13 May 2016 / Victoria White, Digital Content Producer

Reviewing data from the study, the DMC observed that patients receiving riociguat were at a possible increased risk for death and other serious adverse events…

regeneron and bayer

Regeneron and Bayer team up to develop a novel therapy for eye diseases

Industry news / 24 March 2016 / Victoria White

Regeneron and Bayer are to develop a combination therapy of the Ang2 antibody nesvacumab and the VEGF trap aflibercept for the treatment of eye diseases…

nice recommends

NICE recommends five new therapies

Industry news / 27 January 2016 / Victoria White

NICE has published its final recommendations on whether six different drug treatments should be routinely funded by the NHS…

radium-223

NICE recommends Xofigo (radium-223) for prostate cancer

Industry news / 19 November 2015 / Victoria White

NICE’s FAD coincides with a period of great uncertainty with the Cancer Drugs Fund deliberating again whether to remove radium-223 from the list…

eylea

EC approves Eylea for myopic choroidal neovascularisation

Industry news / 30 October 2015 / Victoria White

Bayer plans for an immediate introduction of Eylea to the market with Germany being one of the first launch countries in Europe…

ISIS-FXI-Rx

Isis Pharmaceuticals initiates Phase 2 study of ISIS-FXI Rx in ESRD

Industry news / 30 October 2015 / Victoria White

The Phase 2 study is intended to further characterise the profile of ISIS-FXI Rx and will provide essential data for Bayer’s future clinical development programme for ISIS-FXI Rx…

Regorafenib

Regorafenib now available on NHS Wales for treatment of advanced GIST

Industry news / 24 July 2015 / Victoria White

Regorafenib has been recommended for use on NHS Wales as a third-line treatment for patients with advanced gastrointestinal stromal tumours (GIST).

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +